<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773822</url>
  </required_header>
  <id_info>
    <org_study_id>2018/05</org_study_id>
    <nct_id>NCT03773822</nct_id>
  </id_info>
  <brief_title>Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.</brief_title>
  <acronym>COCCA</acronym>
  <official_title>Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled trial is to evaluate the hemodynamic effect of low&#xD;
      dose corticosteroid therapy (hydrocortisone and fludrocortisone) in the treatment of adult&#xD;
      cardiogenic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiogenic shock is a serious condition with a high mortality rate, characterized by acute&#xD;
      dysfunction of the heart pump. Critical illness-related corticosteroid insufficiency is a&#xD;
      pathophysiological concept, first described in septic shock. It is characterized by an&#xD;
      impairment of the hypothalamic pituitary axis during critical illness. Its diagnosis is&#xD;
      usually suggested by an inappropriate response to the adrenal stimulation test. The results&#xD;
      of corticosteroid supplementation studies in septic shock are controversial, but most of&#xD;
      these studies demonstrate that corticosteroid therapy improves reversal of shock.&#xD;
&#xD;
      The concept of critical illness-related corticosteroid insufficiency has recently been&#xD;
      expanded to cardiogenic shock. The latter has many physiopathological similarities with&#xD;
      septic shock. However, no studies have evaluated the effect of supplemental corticosteroid&#xD;
      supplementation in cardiogenic shock.&#xD;
&#xD;
      The purpose of this study is to evaluate the hemodynamic effect of low dose corticosteroid&#xD;
      therapy in the treatment of adult cardiogenic shock.&#xD;
&#xD;
      This study is a multicenter, randomized, double blinded, placebo controlled trial comparing&#xD;
      intravenous hydrocortisone (50 mg intravenously every 6 hours) plus enteral fludrocortisone&#xD;
      (50 µg/day) with placebo for seven days in critically ill patients with cardiogenic shock.&#xD;
&#xD;
      The primary endpoint for this trial will be catecholamine-fee days at day-7. Secondary&#xD;
      endpoints will include all-cause mortality at 28 and 90 days after randomisation.&#xD;
&#xD;
      Several pre-defined sub-groups analyses are planned, including: postcardiotomy, myocardial&#xD;
      infarction, etomidate use, vasopressor use...&#xD;
&#xD;
      380 patients will be enrolled in this study at approximately 20 study sites. Each patient&#xD;
      will be followed-up for 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2019</start_date>
  <completion_date type="Anticipated">July 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients not treated with corticosteroids at day 7</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 28 and 90 days after randomisation</measure>
    <time_frame>28 and 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of the cardiac index</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care and hospital</measure>
    <time_frame>28 and 90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of support by catecholamines</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of lactatemia</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients use of mechanical ventilation</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Circulatory assistance</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive at day 7 without failure (SOFA) score)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with nosocomial infection</measure>
    <time_frame>28 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of patients requiring the introduction of intravenous insulin therapy after randomization</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of mean arterial pressure</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Placebo of hydrocortisone and placebo of fludrocortisone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of hydrocortisone + fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Hydrocortisone + Flucortac</intervention_name>
    <description>Low dose steroids</description>
    <arm_group_label>Combination of hydrocortisone + fludrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo of hydrocortisone and placebo of fludrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years&#xD;
&#xD;
          2. Cardiogenic shock state, according to the consensual definition:&#xD;
&#xD;
               1. Systemic arterial hypertension (systolic blood pressure &lt;90 mmHg or mean arterial&#xD;
                  pressure ≤ 65 mmHg) or signs of peripheral hypoperfusion, requiring treatment&#xD;
                  with catecholamines to maintain systolic blood pressure ≥ 90 mmHg and regression&#xD;
                  of signs of hypoperfusion;&#xD;
&#xD;
               2. Presence of at least one sign of systemic hypoperfusion among the following:&#xD;
                  marbling, oliguria ≤ 25 ml / h, impairment of consciousness, arterial&#xD;
                  hyperlactatemia&gt; 2 mmol / L;&#xD;
&#xD;
               3. Presence of at least one sign of hypocontractility or low flow among the&#xD;
                  following: cardiac index ≤ 2.2 L / min / m2, left ventricular ejection fraction&#xD;
                  (LVEF) ≤ 40% or full time velocity (ITV) under aortic ≤ 18 cm, or need for&#xD;
                  catecholamines to maintain an index&#xD;
&#xD;
               4. Clinical signs of left and / or right cardiac congestion (clinical sign of acute&#xD;
                  cardiogenic pulmonary edema or jugular turgor or edema of the lower limbs),&#xD;
                  radiological (bilateral alveolar opacities compatible with acute cardiogenic&#xD;
                  pulmonary edema), echocardiography (elevation of filling pressures of the left&#xD;
                  ventricle measured with Doppler: E / A&gt; 2 if LVEF ≤40% or E / Ea&gt; 13 if LVEF&gt;&#xD;
                  40%; or estimated PAPS&gt; 35mmHg) or with right cardiac catheterization (pulmonary&#xD;
                  artery occlusion pressures&gt; 15mmHg or PAPm&gt; 25mmHg)&#xD;
&#xD;
          3. Having received informed information about the study and having signed a consent to&#xD;
             participate in the study&#xD;
&#xD;
          4. Benefiting from a social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiogenic shock state with catecholamine infusion for more than 24 hours;&#xD;
&#xD;
          2. Presence Presence of septic shock at inclusion;&#xD;
&#xD;
          3. Cardiopulmonary arrest recovered in the 7 days preceding inclusion with at least one&#xD;
             early sign of poor prognosis among the following: no control, non-shockable rhythm,&#xD;
             CAHP score (Cardiac Arrest Hospital Prognosis)&gt; 150;&#xD;
&#xD;
          4. Patients already on circulatory support (ECMO) before inclusion (patients who are&#xD;
             assisted after inclusion will not be excluded);&#xD;
&#xD;
          5. Cardiogenic shock on viral myocarditis;&#xD;
&#xD;
          6. Prior corticosteroid therapy (≥ 30 mg prednisone or equivalent ≥ 1 month);&#xD;
&#xD;
          7. Receiving one of the following treatments: ketoconazole, rifampicin, phenytoin,&#xD;
             phenobarbital, cyclosporine and clarithromycin;&#xD;
&#xD;
          8. Known history of hypersensitivity to fludrocortisone or hydrocortisone;&#xD;
&#xD;
          9. Known pregnancy or breastfeeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Armand MEKONTSO DESSAP, MD</last_name>
    <phone>(+33)1 46 25 24 33</phone>
    <email>armand.dessap@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François BAGATE,, MD</last_name>
    <phone>(+33)1 49 81 23 89</phone>
    <email>francois.bagate@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armand MEKONTSO DESSAP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armand MEKONTSO DESSAP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François BAGATE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <state>Le Chasnay</state>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal de Villeneuve Saint Georges</name>
      <address>
        <city>Villeneuve-Saint-Georges</city>
        <state>Villeneuve Saint Georges</state>
        <zip>94190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH de Marne la Vallée - Site Jossigny</name>
      <address>
        <city>Jossigny</city>
        <zip>77600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lille - Institut Cœur Poumon</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud-de-Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CMC Ambroise Paré</name>
      <address>
        <city>Neuilly sur seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre SQUARA, MD</last_name>
      <phone>0146415079</phone>
      <email>recherche@clinique-a-pare.fr</email>
    </contact>
    <contact_backup>
      <last_name>Messaouda MERZOUG, PhD</last_name>
      <email>recherche@clinique-a-pare.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre SQUARA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe ESTAGNASIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain BRUSSET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Driss LAGHLEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Pontoise</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre cardiologique du nord saint denis</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan MORICHAU-BEAUCHANT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clément DELMAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpitaux de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiogenic Shock</keyword>
  <keyword>Steroids</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Fludrocortisone</keyword>
  <keyword>Reversal of shock</keyword>
  <keyword>Mortality</keyword>
  <keyword>Adrenal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

